Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: MEASLES,MUMPS, RUBELLA VACCINE: 0.3ML GIVEN INTRALESIONAL ,EVERY 2 WEEKS UPTO 3 DOSES OR RESOLUTION (WHICHEVER IS EARLIER)
Intervention2: PURIFIED PROTEIN DERIVATIVE: 0.3ML INRALESIONAL
Sponsors
SHUNMADHI
Eligibility
Inclusion criteria
Inclusion criteria: 1. 30 patients aged 12-25 years with verruca vulgaris(less than 20 in number) attending the Dermatology OPD during the study period. 2. Patient who has not undergone any prior systemic or topical treatment. 3. Those who are giving consent to participate in the study. 4. Those who are willing for follow up.
Exclusion criteria
Exclusion criteria: 1. Prior known allergic response to MMR vaccine 2. Patients who received any other treatments for their warts before enrolment. 3. Patients with H/O asthma,allergic skin disorders, meningitis or convulsions 4. Patient with acute febrile illness or signs of any inflammation or infection. 5. Patients with Hepatitis B & Hepatitis C infection 6. Patients with immunosuppression/ HIV Infection 7. Patients with anogenital warts 8. Patients with H/O TB 9. Induration measuring
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.intralesional MMR is better than intralesional PPD 2.Intralesional vaccine is effective against distant wart Timepoint: EVERY 2 WEEKS FOR 3 MONTHS THEN EVERY MONTH UPTO 6 MONTHS OF INITIAL DOSE | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To identify the efficacy of Treatment for local and distant warts. 2. To identify the better treatmentregimen for Verruca vulgaris. 3. To identify the side effects and recurrence rate following treatment. Timepoint: 1 YEAR | — |
Countries
India
Contacts
Public ContactSHUNMADHI S
MADRAS MEDICAL COLLEGE
Outcome results
None listed